Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7701028 | PMC |
| http://dx.doi.org/10.1016/j.jdcr.2020.10.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Erlotinib-induced Perioral Lesions Resembling Scleroderma.
Acta Dermatovenerol Croat
November 2024
Constantin A. Dasanu MD, PhD, Lucy Curci Cancer Center, Eisenhower Health, 39000 Bob Hope Dr, Rancho Mirage, CA 92270 , USA;
Erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is currently used in the therapy of several solid malignancies. This agent has been associated with several dermatological side-effects, the most common being papulo-pustular acneiform rash. Herein we describe a unique skin effect in a patient treated with erlotinib for non-small cell lung cancer.
View Article and Find Full Text PDFCombinational treatment approaches for acanthosis nigricans: a review.
Arch Dermatol Res
January 2025
Fixderma India Pvt Ltd, Sector 54, Gurgaon, 122011, Haryana, India.
Acanthosis Nigricans is characterised by hyperpigmented, hyperkeratotic, dark, rough patches or plaques distributed in intertriginous areas. Hyperkeratosis is the main concern that leads to the darkening of the skin. Numerous treatment options are available.
View Article and Find Full Text PDFPatients with Darier disease have an increased risk of keratinocyte carcinoma: a Swedish registry-based nationwide cohort study.
Orphanet J Rare Dis
December 2024
Department of Dermatology and Venereology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gröna stråket 16, Gothenburg, SE-413 45, Sweden.
Background: Darier disease is a genodermatosis which manifests as hyperkeratotic papules and superficial erosions mainly in seborrheic skin areas. This retrospective registry-based cohort study aimed to estimate the association between Darier disease and skin cancer.
Results: Patients diagnosed with Darier disease were identified from the patient registry of Sahlgrenska University Hospital (Gothenburg, Sweden) in 2016-2020.
Case report: Abrocitinib: a potential therapeutic option for lichen amyloidosis associated with atopic dermatitis.
Front Immunol
November 2024
School of Medicine, Tongji University, Shanghai, China.
Lichen amyloidosis (LA) is a predominant type of primary cutaneous amyloidosis that is characterized by persistent and intense skin itching. Although multiple therapeutics strategies are available for its treatment, there is no standard treatment so far. Abrocitinib, an oral small-molecule Janus kinase 1 inhibitor, has been authorized for the treatment of severe atopic dermatitis (AD) and can also provide rapid relief from pruritus.
View Article and Find Full Text PDFTh1 and Th2 cytokine expression in hyperkeratotic chronic hand eczema and the role of Tofacitinib a oral JAK inhibitor.
Arch Dermatol Res
October 2024
Department of Dermatology, Venereology and Leprosy, Atal Bihari Vajpayee Institute of Medical Sciences and Research Institute and Dr. Ram Manohar Lohia Hospital, New Delhi, India.
Article Synopsis
- * A study analyzed tissue samples from 11 patients with difficult-to-treat CHE, finding increased levels of key cytokines (IL-4, TNF-α, IFN-γ) compared to unaffected skin.
- * Tofacitinib was administered to 15 patients, showing promising results with a mean improvement in eczema severity after 4 weeks, although some experienced side effects and relapses after stopping treatment.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!